{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:30:49Z","timestamp":1760866249741,"version":"3.41.2"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00676","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T05:58:48Z","timestamp":1588744728000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma"],"prefix":"10.3389","volume":"10","author":[{"given":"Arthur","family":"Bobin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Gardeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Sabirou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Gruchet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"L\u00e9vy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laly","family":"Nsiala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cailly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Tomowiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Torregrosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Guidez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/14656566.2019.1577822","article-title":"The pharmacologic management of multiple myeloma in older adults","volume":"20","author":"Dempsey","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)","volume":"32","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated with continuous lenalidomide plus low-dose dexamethasone in the first (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet Haematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1111\/bjh.16194","article-title":"A novel Haemato-oncology Frailty (HOF) score tool predicts survival in over 80s with Multiple Myeloma","volume":"187","author":"Hinton","year":"2019","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1182\/asheducation-2010.1.437","article-title":"Thrombosis in multiple myeloma","volume":"2010","author":"Kristinsson","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues","volume":"11","author":"Delforge","year":"2010","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/cam4.1128","article-title":"The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study","volume":"6","author":"Gregersen","year":"2017","journal-title":"Cancer Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1182\/blood-2018-99-111796","article-title":"Efficacy and Feasibility of Dose\/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study","volume":"132","author":"Larocca","year":"2018","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma (relapse\/refractory)","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/hon.2439_152","article-title":"DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (CASTOR)","volume":"35","author":"Lentzsch","year":"2017","journal-title":"Hematol Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1182\/blood-2019-123483","article-title":"Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)","volume":"134","author":"Kaufman","year":"2019","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1016\/j.clml.2019.09.333","article-title":"A Matching-Adjusted Indirect Comparison (MAIC) of Daratumumab-Bortezomib-Thalidomide-Dexamethasone (D-VTd) Versus Bortezomib-Lenalidomide-Dexamethasone (VRd) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible","volume":"19","author":"Moreau","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B25","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1182\/blood-2019-123426","article-title":"Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia","volume":"134","author":"Bahlis","year":"2019","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2217\/fon-2017-0616","article-title":"Isatuximab plus pomalidomide\/dexamethasone versus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma: ICARIA Phase III study design","volume":"14","author":"Richardson","year":"2018","journal-title":"Futur Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1182\/blood-2019-122765","article-title":"Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjh.14787","article-title":"Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth","volume":"178","author":"Dimopoulos","year":"2017","journal-title":"Br J Haematol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: Elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.clml.2015.12.007","article-title":"Pharmacokinetics and Safety of Elotuzumab Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study","volume":"16","author":"Berdeja","year":"2016","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies","volume":"34","author":"Lesokhin","year":"2014","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"LBA3001","DOI":"10.1200\/jco.2017.35.18_suppl.lba3001","article-title":"Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory\/relapsed multiple myeloma","volume":"35","author":"Fan","year":"2017","journal-title":"J Clin Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1182\/blood.V130.Suppl_1.740.740","article-title":"Durable clinical responses in heavily pretreated patients with relapsed\/refractory multiple myeloma: Updated results from a multicenter study of BB2121 anti-BCMA car T cell therapy","volume":"130","author":"Berdeja","year":"2017","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor with a CD28 costimulatory moiety cause remissions of poor-prognosis relapsed multiple myeloma clinically relevant abstract","volume":"36","author":"Brudno","year":"2017","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/cas.12631","article-title":"Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma","volume":"106","author":"Zou","year":"2015","journal-title":"Cancer Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00676\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T05:58:50Z","timestamp":1588744730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00676\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":43,"alternative-id":["10.3389\/fonc.2020.00676"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00676","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"article-number":"676"}}